Lilly Terminates Phase 3 Development of Type 2 Diabetes Drug

Eli Lilly has elected not to advance Transition Therapeutics’ candidate to control glucose and stimulate weight loss in patients with Type 2 diabetes.

Transition said the drug giant handed back the development and commercialization rights to TT401 to the Toronto-based company, and it has the option to advance the candidate on its own or with a partner.

Tony Cruz, CEO of Transition, said that TT401 may have not demonstrated enough superiority on weight loss for Lilly to advance into Phase 3. Lilly could not be reached for comment by press time.